Cure8 research brief
Phages shape the gut microbial community and may behave differently in inflamed guts. Understanding phage evolution in IBD could eventually inform microbiome-targeted therapies or explain disease-associated microbial shifts.
Researchers studying the gut microbiome, virome, and phage therapy; clinicians interested in microbiome science; scientists researching IBD pathogenesis.
This abstract reports a basic-science preprint studying bacteriophages (viruses that infect bacteria) associated with Phocaeicola vulgatus in gut samples from healthy people and people with Crohn’s disease. Using viral tagging, the authors recovered tailed BV01-like phages and a newly identified filamentous phage (PvIno1).
They describe different patterns of genetic diversification: BV01-like phages showed mutations in tail genes and variable tail-fiber shufflon configurations that differed between health and Crohn’s disease, while the filamentous PvIno1 showed diversification focused in a regulatory region.
The authors interpret these differences as evidence that inflammation imposes different evolutionary pressures on distinct phage types, and suggest that integrating phage evolutionary dynamics with ecological models could inform future phage-based therapies for gut dysbiosis.
This is presented as a preprint abstract and summarizes experimental observations rather than clinical results.
This record is a preprint abstract (structured content depth: abstract). It reports laboratory-based evolutionary and virome analyses, not clinical trials or patient treatments. Findings have not completed peer review and do not imply therapeutic benefit yet.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.
The study suggests that in IBD the gut microbiome’s functional impact on immune signalling is shifted toward inflammation even when composition appears similar to controls.
Identifies oral microbes that may appear in the gut of people with IBD and PSC, which could help researchers understand disease mechanisms and eventually inform diagnostics or microbiome-targeted strategies.
